CLINUVEL: Record Half-Year Confirms Growth Trajectory – PARMANTIER & CIE. Presents Latest Research Study on CLINUVEL Pharmaceuticals' Half-Year Results

Frankfurt am Main, March 7, 2025 – CLINUVEL Pharmaceuticals Ltd. (ASX: CUV - ADR Level1: CLVLY – Frankfurt/M Stock Exchange: UR9 - ISIN: AU000000CUV3) continues its impressive growth trajectory, reporting record-breaking figures for the first half of fiscal year 2025.
The company has surpassed market expectations, delivering a +21.1% revenue increase to AU$ 43.3 million, confirming its strong operational performance and the effectiveness of its innovative business strategy. Earnings per share (EPS) rose +27.4% to 28.1 cents, while cash reserves grew to AU$ 198.2 million (+7.8%).

Dr. Philippe Wolgen – The Architect of CLINUVEL’s Sustainable Success
This performance underscores the strong operational efficiency and sustainable growth potential of the company. CEO Dr. Philippe Wolgen’s leadership has transformed CLINUVEL over the past two decades from a specialized biotech company into a profitable, globally operating leader with a unique business model.
Under his guidance, SCENESSE® was successfully developed, approved, and commercialized worldwide, while the company simultaneously expanded into new business areas like "PhotoCosmetics". His strategic execution has positioned CLINUVEL on a steady growth trajectory, both in pharmaceutical innovation and novel photomedicine solutions.
A leadership change at this stage would be counterproductive to CLINUVEL’s ambitious growth strategy. Dr. Wolgen’s deep expertise, strategic foresight, and proven track record make him the ideal leader for CLINUVEL.
His long-term vision is crucial for the next phase of growth, particularly in the following key areas:
1. Vitiligo therapy: Advancing SCENESSE® for Vitiligo, targeting approval by 2028
2. North American expansion: Establishing 120 specialized treatment centers for EPP and Vitiligo patients
3. New product lines: Launching CYACÊLLE Radiant, a cutting-edge non-pharmaceutical product, in late 2025
The coming years will be driven by strategic foresight and decisive action—qualities Dr. Wolgen has consistently demonstrated, ensuring CLINUVEL’s continued success.

Financial Highlights H1/FY25:

• Total revenue: AU$ 43.3 million (+21.1% YoY)
• Commercial sales: AU$ 32.6 million (+9.2%)
• SCENESSE® revenue under the Special Access Scheme: AU$ 3.0 million (+25%)
• Net profit: AU$ 14.1 million (+28.7%)
• Cash reserves: AU$ 198.2 million (+7.8%)

A major driver of future growth is the expansion of CLINUVEL’s network of specialized treatment centers in North America, targeting 120 locations by the end of 2025.


Our full research report on the latest developments at CLINUVEL Pharmaceuticals is available at:
Bloomberg/parmantiercie; Short code: {DS FMG <GO>}
PARMANTIER & CIE. Research www.parmantiercie.com/research


About PARMANTIER & CIE. GmbH:
PARMANTIER & CIE. specializes in advising and facilitating corporate financing solutions, including equity, debt, and hybrid financing. As a modern Merchant Bank, the company combines traditional values with innovative financing solutions, investing in both publicly traded and private companies.
With a strong commitment to independent investment strategies, PARMANTIER & CIE. provides tailor-made financial solutions, particularly for growth companies in technology, healthcare, and sustainable industries.


Contact:
PARMANTIER & Cie. GmbH
info@parmantiercie.com
www.parmantiercie.com